About Transmembrane protein 181
Transmembrane protein 181 (TMEM181) is a protein
from Homo sapiens identified by UniProt accession
Q9P2C4, 475 residues long.
MolForge cross-references it against 0 known binders and
27 disease associations.
Target properties
| Protein name | Transmembrane protein 181 |
| UniProt accession | Q9P2C4 |
| Gene | TMEM181 |
| Organism | Homo sapiens |
| Length | 475 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (27)
Diseases linked to this target (Open Targets).
- glaucoma · score 0.26
- lipoprotein A measurement · score 0.26
- open-angle glaucoma · score 0.26
- intraocular pressure measurement · score 0.26
- protein measurement · score 0.17
- body height · score 0.14
- heel bone mineral density · score 0.13
- smoking status measurement · score 0.13
- vital capacity · score 0.11
- appendicular lean mass · score 0.11
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9P2C4-F1 | alphafold | PREDICTED | 78.08 | — |
Amino-acid sequence (475 residues)
MEPLAPMRLY TLSKRHFVLV FVVFFICFGL TIFVGIRGPK VIQTSAANFS LNNSKKLKPI QILSNPLSTY NQQLWLTCVV ELDQSKETSI KTSFPMTVKV DGVAQDGTTM YIHNKVHNRT RTLTCAGKCA EIIVAHLGYL NYTQYTVIVG FEHLKLPIKG MNFTWKTYNP AFSRLEIWFR FFFVVLTFIV TCLFAHSLRK FSMRDWGIEQ KWMSVLLPLL LLYNDPFFPL SFLVNSWLPG MLDDLFQSMF LCALLLFWLC VYHGIRVQGE RKCLTFYLPK FFIVGLLWLA SVTLGIWQTV NELHDPMYQY RVDTGNFQGM KVFFMVVAAV YILYLLFLIV RACSELRHMP YVDLRLKFLT ALTFVVLVIS IAILYLRFGA QVLQDNFVAE LSTHYQNSAE FLSFYGLLNF YLYTLAFVYS PSKNALYESQ LKDNPAFSML NDSDDDVIYG SDYEEMPLQN GQAIRAKYKE ESDSD
Explore Transmembrane protein 181 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets